GeneOne Life Science Inc (011000.KS)
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company's nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C re-infection prophylaxis, as well as GLS-6100 that is in pre-clinical stage for hepatitis C prophylaxis. Further, the company's discovery and optimization stage pipeline comprise GLS-7000 for the treatment of breast cancer; GLS-7100 for treating hemophilia A; GLS-8000 for the prevention of chronic hepatitis B; and GLS-8100 for treating rheumatoid arthritis. Additionally, it engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩273.82B
₩37.19B
-₩10.44B
₩1,830.00 - ₩4,735.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
GeneOne Life Science Inc (011000.KS) returned 62.41% year-to-date (YTD) and 51.66% over the past 12 months. Over the past 10 years, 011000.KS returned -11.11% annually, underperforming the S&P 500 benchmark at 10.85%.
011000.KS
62.41%
61.65%
59.03%
51.66%
-34.99%
-13.06%
-11.11%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 011000.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0.95% | 4.92% | -10.89% | 15.98% | 48.38% | 62.41% | |||||||
| 2024 | -11.09% | 1.19% | -0.78% | -2.96% | -7.93% | -9.71% | 54.28% | -12.68% | -5.08% | -4.40% | -13.60% | -2.08% | -25.53% |
| 2023 | 18.91% | -15.67% | -11.17% | -5.66% | -16.67% | -22.00% | 10.26% | -9.19% | -9.48% | -19.94% | 3.36% | -2.91% | -60.22% |
| 2022 | -24.07% | 19.11% | 2.05% | -25.08% | 11.61% | -17.60% | 29.13% | -18.80% | -11.85% | -22.37% | -5.68% | 2.44% | -55.93% |
| 2021 | -22.97% | -15.06% | -17.02% | 48.72% | 31.61% | 106.55% | -12.26% | -20.60% | 4.10% | -25.39% | 17.76% | -17.63% | 15.20% |
| 2020 | 73.03% | -7.91% | 235.94% | -27.91% | 24.77% | -8.58% | -7.12% | 218.89% | 3.31% | -4.72% | -4.42% | -20.19% | 878.87% |
| 2019 | 21.43% | -9.96% | -6.22% | 7.19% | -2.83% | -3.99% | -10.56% | -0.50% | 5.30% | -1.68% | -33.17% | -1.63% | -37.90% |
| 2018 | 18.78% | -1.99% | -1.31% | 7.66% | 1.09% | -16.78% | -5.53% | 5.85% | 4.55% | -29.70% | 11.95% | -14.23% | -26.57% |
| 2017 | -8.09% | -3.24% | -6.32% | -1.84% | 7.18% | -1.46% | -14.88% | -7.75% | -16.50% | 3.44% | -0.79% | -5.74% | -45.22% |
| 2016 | 51.40% | -13.58% | 11.43% | 6.41% | -4.82% | -3.16% | 3.27% | -11.39% | -1.07% | -20.22% | 3.17% | 3.07% | 9.81% |
| 2015 | -3.94% | -15.84% | 0.90% | 21.55% | 111.49% | -25.14% | -16.99% | 52.56% | -19.21% | 4.15% | -7.97% | -15.75% | 29.70% |
| 2014 | 10.00% | -15.27% | 3.86% | -19.26% | -0.82% | -0.21% | 7.55% | 11.95% | 7.94% | 58.01% | 7.12% | -15.60% | 43.63% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 011000.KS is 73, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for GeneOne Life Science Inc (011000.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the GeneOne Life Science Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GeneOne Life Science Inc was 95.71%, occurring on Jan 8, 2020. Recovery took 368 trading sessions.
The current GeneOne Life Science Inc drawdown is 90.88%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.71% | Feb 17, 2006 | 3407 | Jan 8, 2020 | 368 | Jul 2, 2021 | 3775 |
| -94.98% | Jul 21, 2021 | 911 | Apr 9, 2025 | — | — | — |
| -87.15% | Dec 17, 1996 | 241 | Dec 12, 1997 | 746 | Jan 9, 2001 | 987 |
| -81.31% | Feb 7, 2001 | 797 | May 18, 2004 | 284 | Jul 15, 2005 | 1081 |
| -50.54% | Oct 25, 2005 | 16 | Nov 15, 2005 | 15 | Dec 6, 2005 | 31 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of GeneOne Life Science Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of GeneOne Life Science Inc, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how GeneOne Life Science Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 011000.KS compared to other companies in the Biotechnology industry. 011000.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 011000.KS relative to other companies in the Biotechnology industry. Currently, 011000.KS has a P/S ratio of 7.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 011000.KS in comparison with other companies in the Biotechnology industry. Currently, 011000.KS has a P/B value of 3.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |